Completed Hemophilia B trials in Japan: Trial Insights

Filters: Condition: Hemophilia B Status: Completed Country / region: Japan Clear all

27 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2007	1
2008	1
2009	4
2010	1
2011	4
2012	5
2013	1
2014	2
2015	1
2016	1
2018	4
2019	1
2020	1

Trials by status
Category	Trials
Completed	27

Top lead sponsors
Category	Trials
Novo Nordisk A/S	10
Baxalta now part of Shire	5
Pfizer	3
Bayer	2
Bioverativ Therapeutics Inc.	2
CSL Behring	2
Genzyme, a Sanofi Company	2
Weill Medical College of Cornell University	1

Top conditions
Category	Trials
Hemophilia B	27
Hemophilia A	12
Blood Coagulation Disorders	2
Blood Coagulation Disorders, Inherited	2
Coagulation Protein Disorders	2
Genetic Diseases, Inborn	2
Genetic Diseases, X-Linked	2
Hematologic Diseases	2
Hemorrhagic Disorders	2
Hemorrhage	1

Trials

Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B NCT03938792Phase 3CompletedPfizerStarted 2020
Post-marketing Surveillance (Use Result Surveillance) With Refixia® NCT03875547ObservationalCompletedNovo Nordisk A/SStarted 2019
A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) NCT03741881ObservationalCompletedNovo Nordisk A/SStarted 2018
A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) NCT03587116Phase 3CompletedPfizerStarted 2018
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors NCT03417245Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors NCT03417102Phase 3CompletedGenzyme, a Sanofi CompanyStarted 2018
RIXUBIS Drug Use-Result Survey (Japan) NCT02937831ObservationalCompletedBaxalta now part of ShireStarted 2016
A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors NCT02571569Phase 1CompletedBayerStarted 2015
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B NCT02141074Phase 3CompletedNovo Nordisk A/SStarted 2014
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B NCT02053792Phase 3CompletedCSL BehringStarted 2014
Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen NCT01757405Phase 3CompletedBaxalta now part of ShireStarted 2013
A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 NCT01625390Phase 2/3CompletedBayerStarted 2012
Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B NCT01386528Phase 3CompletedNovo Nordisk A/SStarted 2012
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. NCT01467427Phase 3CompletedNovo Nordisk A/SStarted 2012
Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 NCT01395810Phase 3CompletedNovo Nordisk A/SStarted 2012
A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B NCT01496274Phase 2/3CompletedCSL BehringStarted 2012
Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B NCT01425723Phase 3CompletedBioverativ Therapeutics Inc.Started 2011
Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients NCT01333111Phase 3CompletedNovo Nordisk A/SStarted 2011
BAX 326 (rFIX) Continuation Study NCT01286779Phase 3CompletedBaxalta now part of ShireStarted 2011
Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients NCT01288391Phase 1CompletedNovo Nordisk A/SStarted 2011
Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients NCT01174446Phase 3CompletedBaxalta now part of ShireStarted 2010
Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B NCT01027364Phase 3CompletedBioverativ Therapeutics Inc.Started 2009
BeneFIX Drug Use Results Survey [All-Case Surveillance] NCT01154231ObservationalCompletedPfizerStarted 2009
Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B NCT00956345Phase 1CompletedNovo Nordisk A/SStarted 2009
Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor NCT00851721Phase 3CompletedBaxalta now part of ShireStarted 2009

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory